The Fourth Tier: Tighter Control of Specialty Drugs


Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

SKU: 1146. Category: .

Product Description

Managed care organizations are tackling the rising costs and expanding use of specialty products. Specialty drugs, injectable biologics, and other higher-cost drugs that require close supervision and monitoring are the fastest-growing segment of the overall pharmaceutical space.
The average annual increase in drug cost expenditures reported in 2007 was 6.9%, according to the Pharmacy Benefit Management Institute‚Äôs (PBMI) 2007 Prescription Drug Benefit Cost and Plan Design Report released in October 2007…

The top six specialty categories
2007 to 2010 Forecast for selected specialty therapy classes

Experts on this Topic
Michael Goodman. VP, Research Products, AVOS Life Sciences, Raleigh, N.C.; AVOS Life Sciences is a boutique advisory and research products company. For more information, visit
Michael Jacobs. National Clinical Practice Leader, Buck Consultants LLC, New York; Buck Consultants provides human resource and benefits consulting through more than 1,500 professionals worldwide. For more information, visit
Tony Lanzone. VP, Trade and Distribution Practice, Campbell Alliance, Raleigh, N.C.; Campbell Alliance is a management consulting firm
specializing in the pharmaceutical and biotechnology industries. For more information, visit